News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,298 Results
Type
Article (8055)
Company Profile (140)
Press Release (476198)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166772)
Career Advice (305)
Deals (25742)
Drug Delivery (7)
Drug Development (52888)
Employer Resources (14)
FDA (9760)
Job Trends (8575)
News (238218)
Policy (17907)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (488)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33165)
ALS (104)
Alzheimer's disease (973)
Antibody-drug conjugate (ADC) (262)
Approvals (10367)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6964)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (506)
Cancer (3624)
Cardiovascular disease (217)
Career advice (246)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (476)
Cervical cancer (34)
Clinical research (47846)
Collaboration (1236)
Commercialization (3)
Compensation (1444)
Complete response letters (34)
COVID-19 (756)
CRISPR (63)
C-suite (735)
Cystic fibrosis (85)
Data (5606)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4175)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73571)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87591)
Executive appointments (698)
FDA (12361)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (906)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (290)
Government (949)
Grass and pollen (2)
Guidances (281)
Healthcare (9323)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (155)
Infectious disease (944)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (42)
IPO (12388)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5209)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (502)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (525)
Marketing (8)
MASH (118)
Medical device (8649)
Medtech (8789)
Mergers & acquisitions (14381)
Metabolic disorders (703)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1815)
NextGen: Class of 2026 (3157)
Non-profit (846)
Obesity (222)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (471)
Patient recruitment (501)
Peanut (31)
People (41229)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15462)
Phase 2 (21370)
Phase 3 (14390)
Pipeline (7135)
Policy (18)
Postmarket research (1572)
Preclinical (6540)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3021)
Recruiting (6)
Regulatory (14790)
Reports (20)
Research institute (582)
Resumes & cover letters (46)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (120)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2022)
Stomach cancer (3)
Supply chain (50)
Vaccines (317)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (91)
Last 7 days (534)
Last 30 days (1612)
Last 365 days (19149)
2026 (11895)
2025 (19251)
2024 (22988)
2023 (26547)
2022 (34602)
2021 (37168)
2020 (33469)
2019 (23276)
2018 (17472)
2017 (18769)
2016 (17921)
2015 (24269)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20443)
2010 (20332)
Location
Africa (228)
Alabama (72)
Alaska (2)
Arizona (299)
Arkansas (11)
Asia (17874)
Australia (2097)
California (11843)
Canada (3114)
China (513)
Colorado (479)
Connecticut (405)
Delaware (207)
Europe (24611)
Florida (1770)
Georgia (371)
Hawaii (3)
Idaho (46)
Illinois (693)
India (48)
Indiana (314)
Iowa (14)
Japan (396)
Kansas (100)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1187)
Massachusetts (7802)
Michigan (306)
Minnesota (558)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2599)
New Mexico (12)
New York (2800)
North Carolina (1262)
North Dakota (4)
Northern California (5927)
Ohio (275)
Oklahoma (14)
Oregon (16)
Pennsylvania (2239)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4914)
Tennessee (119)
Texas (1913)
United States (38511)
Utah (357)
Vermont (1)
Virginia (152)
Washington D.C. (38)
Washington State (917)
West Virginia (1)
Wisconsin (73)
484,298 Results for "viacyte inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy
Partners CRISPR and ViaCyte (Vertex), and Genprex are pioneers in the quest to develop a gene therapy for Type 1 diabetes.
March 10, 2023
·
3 min read
·
Jia Jie Chen
Deals
Vertex Buys ViaCyte in Synergistic Deal Aimed at Curing Type 1 Diabetes
Vertex Pharmaceuticals plans to acquire ViaCyte for $320 million in cash. ViaCyte focuses on stem cell-derived cell replacement therapies that they hope will cure type 1 diabetes (T1D).
July 11, 2022
·
3 min read
·
Mark Terry
Business
Vertex’s Viacyte Backs Out of CRISPR Diabetes Deal
Vertex still has an ongoing diabetes partnership with CRISPR, which gives it a non-exclusive license to the latter’s platform to develop a potential cure for type 1 diabetes.
January 9, 2024
·
2 min read
·
Tristan Manalac
Business
ViaCyte Appoints Marty Lorenzo as General Counsel
ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, announced the appointment of Marty Lorenzo as General Counsel.
November 30, 2021
·
2 min read
Biotech Beach
ViaCyte to Present at the Jefferies Gene Therapy/Editing Summit
ViaCyte, Inc. will present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 11:30 a.m. ET
October 20, 2021
·
1 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Biotech Beach
ViaCyte to Participate in 2022 Advanced Technologies & Treatments for Diabetes Conference
Manasi Sinha Jaiman, M.D., M.P.H., who was recently appointed Chief Medical Officer at Viacyte Inc., will participate in the 15th International Conference on Advanced Technologies & Treatments for Diabetes’ (ATTD) session, Utility of PROs in Therapy Development for Type 1 Diabetes: Putting the End-User Upfront.
April 20, 2022
·
2 min read
Biotech Beach
ViaCyte Chief Scientific Officer to Deliver Keynote Address at JDRF Mission Summit
ViaCyte, Inc. announced today that the Company’s Chief Scientific Officer, Timothy Kieffer , Ph.D., will deliver the keynote address at the 10th JDRF Mission Summit.
December 3, 2021
·
2 min read
Business
ViaCyte Appoints Dr. Jon Wilensky as Head of Surgery
ViaCyte, Inc., an innovator in cellular therapy and regenerative medicine, announced that it has appointed Jon Wilensky, MD, MBA, FACS, as Head of Surgery.
July 21, 2021
·
3 min read
Drug Development
CRISPR and ViaCyte Dose First Patient in Historic Type 1 Diabetes Trial
CRISPR Therapeutics and ViaCyte dosed their first patient in Phase I clinical trial of a novel gene-edited cell replacement therapy to treat Type 1 Diabetes.
February 3, 2022
·
2 min read
·
Hayley Shasteen
1 of 48,430
Next
